C-Path’s Predictive Safety Testing Consortium (PSTC) has launched the Biomarker Data Repository (BmDR): a repository for data on novel translational safety biomarkers from drug development programs. Masked, de-identified data from multiple sponsors will be collected and stored in a secured repository. The data will then be available to C-Path and FDA staff to support research that leads to the submission of documents to worldwide regulatory agencies to qualify novel safety biomarkers for new Contexts of Use (CoUs), to modify and expand existing CoUs, and to identify appropriate exploratory biomarkers to advance drug development in the future. The initial pilot focuses on kidney safety biomarkers.
The main goal of the BmDR is to provide industry with new drug development tools. Existing biomarker data could be used to significantly advance and accelerate understanding of the utility of novel biomarkers as drug development tools.
As a sponsor, you can join with other innovative companies simply by sharing non-proprietary data. Since only summary, non-proprietary data will be available, each participating organization’s intellectual property is protected. C-Path has set up a straightforward governance process that protects all submitted data through sponsor-directed data use agreements. Contributors to BmDR will have access to aggregated biomarker data and summary analyses—enabling collaboration and support of their drug development efforts, reference ranges, medically relevant thresholds, and other outputs from accumulated data on both conventional and novel biomarkers.
Please feel free to contact us if you have any questions or need additional information: email@example.com